𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recent and emerging anti-diabetes targets

✍ Scribed by Michael L. Mohler; Yali He; Zhongzhi Wu; Dong Jin Hwang; Duane D. Miller


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
962 KB
Volume
29
Category
Article
ISSN
0198-6325

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Diabetes is a disease that affects over 150 million people worldwide for which there are multiple oral and injectable medications. Because of trends in obesity and sedentary lifestyles, diabetes rates in both developed and developing countries are increasing at an alarming rate. Current medications are not adequately effective in maintaining long‐term glycemic control in most patients, even when used in combination, leaving diabetics susceptible to developing life threatening and debilitating complications such as cardiovascular disease, blindness, kidney complications, and amputations. Consequently, there is a critical need for more potent pharmacotherapies with novel mechanisms of action. A panel of 20 emerging diabetes targets is presented, and small molecule modulators for each target will be discussed. Β© 2008 Wiley Periodicals, Inc. Med Res Rev, 29, No. 1, 125–195, 2009


πŸ“œ SIMILAR VOLUMES


ChemInform Abstract: Recent and Emerging
✍ Michael L. Mohler; Yali He; Zhongzhi Wu; Dong Jin Hwang; Duane D. Miller πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons βš– 15 KB

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a β€œFull Text” option. The original article is trackable v

New anti-HIV Agents and Targets
✍ Erik De Clercq πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons βš– 69 KB πŸ‘ 2 views

## Abstract For Abstract see ChemInform Abstract in Full Text.

New anti-HIV agents and targets
✍ Erik De Clercq πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 463 KB πŸ‘ 1 views

## Abstract Virtually all the compounds that are currently used or are subject of advanced clinical trials for the treatment of HIV infections, belong to one of the following classes: (i) nucleoside reverse transcriptase inhibitors (NRTIs): i.e., zidovudine, didanosine, zalcitabine, stavudine, lami